ストックスクリーナーアプリを入手
10.61
0.56%
-0.06
前日終値:
$10.67
開ける：
$10.76
24時間の取引高:
2.12M
Relative Volume:
0.76
時価総額：
$1.41B
収益：
-
当期純損益:
$-766.97M
株価収益率:
-1.3851
EPS:
-7.66
ネットキャッシュフロー:
$-646.43M
1週間 パフォーマンス:
-7.82%
1か月 パフォーマンス:
-3.46%
6か月 パフォーマンス:
-33.98%
1年 パフォーマンス:
-66.18%
1日の値動き範囲:
$10.15
$10.78
1週間の範囲:
$10.15
$11.91
52週間の値動き範囲:
$7.48
$31.87
Biohaven Ltd Stock (BHVN) Company Profile
Compare BHVN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
10.61 | 1.42B | 0 | -766.97M | -646.43M | -7.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-06 | 開始されました | Goldman | Buy |
| 2026-01-21 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | ダウングレード | UBS | Buy → Neutral |
| 2025-11-06 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-09-17 | 開始されました | Citigroup | Buy |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-05-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-09-16 | 開始されました | Jefferies | Buy |
| 2024-09-04 | 開始されました | Bernstein | Outperform |
| 2024-07-24 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-16 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-02-06 | 開始されました | UBS | Buy |
| 2023-12-22 | 開始されました | H.C. Wainwright | Buy |
| 2023-12-08 | 開始されました | Robert W. Baird | Outperform |
| 2023-01-24 | 開始されました | SVB Securities | Outperform |
| 2023-01-04 | 開始されました | JP Morgan | Overweight |
| 2022-12-02 | 開始されました | BTIG Research | Buy |
| 2022-10-26 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 開始されました | Piper Sandler | Overweight |
| 2022-08-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-05-11 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-08-10 | ダウングレード | UBS | Buy → Neutral |
| 2021-08-03 | 繰り返されました | Canaccord Genuity | Buy |
| 2021-03-11 | 開始されました | UBS | Buy |
| 2020-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-17 | 開始されました | Cowen | Outperform |
| 2020-02-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2019-11-22 | 開始されました | Wedbush | Outperform |
| 2019-06-25 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-05-06 | 開始されました | Goldman | Buy |
| 2019-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 繰り返されました | Needham | Buy |
| 2018-07-03 | 繰り返されました | Needham | Buy |
| 2018-07-02 | 繰り返されました | Needham | Buy |
| 2018-04-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 繰り返されました | Canaccord Genuity | Buy |
| 2017-12-15 | 開始されました | Canaccord Genuity | Buy |
| 2017-10-03 | 繰り返されました | Needham | Buy |
すべてを表示
Biohaven Ltd (BHVN) 最新ニュース
Biohaven stock price target lowered to $10 by H.C. Wainwright - Investing.com South Africa
Biohaven (NYSE:BHVN) Given New $10.00 Price Target at HC Wainwright - MarketBeat
BHVN Earnings History & Surprises | EPS & Revenue Results | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Assessing Biohaven (BHVN) Valuation After Recent Share Price Volatility - simplywall.st
Biohaven Reshapes Pipeline And Funding As Late Stage Trials Approach - Yahoo Finance
Biohaven (BHVN) VP and CAO awarded 50,000 stock options with 4-year vesting - Stock Titan
Biohaven (BHVN) CFO awarded 175,000 stock options in Form 4 filing - Stock Titan
Biohaven Ltd. (BHVN) SVP awarded 175,000 stock options with 4-year vesting - Stock Titan
Biohaven (BHVN) Chief Scientific Officer awarded 175,000 stock options - Stock Titan
Biohaven (BHVN) CEO Vlad Coric granted 550,000 stock options - Stock Titan
Key facts: Biohaven posts $738.8M loss; opakalim shows promise in study; analysts give 'buy' rating - TradingView
Biohaven (NYSE:BHVN) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Piper Sandler reiterates Biohaven stock rating on 2026 catalysts By Investing.com - Investing.com Canada
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 77% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Piper Sandler reiterates Biohaven stock rating on 2026 catalysts - Investing.com
RBC Raises Price Target on Biohaven to $23 From $22, Keeps Outperform, Speculative Risk - marketscreener.com
JPMorgan Chase & Co. Reduces Stake in Biohaven Ltd. $BHVN - MarketBeat
Biohaven Ltd. Common Shares (NY: BHVN - The Chronicle-Journal
Biohaven Ltd reports results for the quarter ended September 30Earnings Summary - TradingView
Biohaven (NYSE:BHVN) Announces Earnings Results - MarketBeat
Biohaven (NYSE: BHVN) refocuses pipeline after key trial and FDA setbacks - Stock Titan
Earnings Flash (BHVN) Biohaven Ltd. Posts Q4 Adjusted Loss $0.90 per Share, vs. FactSet Est of $-0.87 - marketscreener.com
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results - PR Newswire
How US$600 Million Non-Dilutive Funding and R&D Cuts Will Impact Biohaven (BHVN) Investors - Sahm
Biohaven Ltd. (BHVN): A Bull Case Theory - Yahoo Finance
BHVN Should I Buy - Intellectia AI
Assessing Biohaven (BHVN) Valuation After A Sharp One Year Decline And Recent Three Month Rebound - simplywall.st
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biohaven Ltd. (BHVN) Stock Analysis: Navigating a Potential 80% Upside in the Biotechnology Sector - DirectorsTalk Interviews
Trading the Move, Not the Narrative: (BHVN) Edition - Stock Traders Daily
Biohaven (BHVN) Projected to Post Earnings on Monday - MarketBeat
Is Biohaven Ltd. stock a good pick for beginnersWeekly Trade Report & Expert Curated Trade Setup Alerts - mfd.ru
Biohaven Ltd. (BHVN) Stock Analysis: A Biotech Challenger With An 84% Potential Upside - DirectorsTalk Interviews
Raymond James Begins Coverage of Biohaven with Strong Buy Rating and Sets Price Target at $75 - Intellectia AI
What catalysts could drive Biohaven Ltd. stock higherTrade Exit Summary & Real-Time Volume Analysis - mfd.ru
Biohaven CEO Vlad Coric to Present at J.P. Morgan Healthcare Conference on January 12, 2026 - Intellectia AI
Biohaven Reveals Pricing for $175 Million Public Offering of Common Stock - Intellectia AI
Aug Drivers: Is Biohaven Ltd. in a bullish channelWeekly Trend Recap & Safe Entry Trade Reports - mfd.ru
'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments - Fierce Biotech
(BHVN) Volatility Zones as Tactical Triggers - Stock Traders Daily
Biohaven Stock Surges 8.4% After Analyst Upgrade - National Today
Assessing Biohaven (BHVN) Valuation As Analyst Optimism And Earnings Estimates Improve - simplywall.st
RSI Check: Can Biohaven Ltd deliver alpha2025 Technical Patterns & Expert Verified Movement Alerts - baoquankhu1.vn
Biohaven Ltd. (BHVN): Analyst Consensus Points to 63% Upside Potential Amidst Biotech Innovation - DirectorsTalk Interviews
Does Biohaven Ltd. (BHVN) have the potential to rally 82.16% as Wall Street analysts expect? - MSN
Big Money Moves: What are analysts price targets for Biohaven LtdWall Street Watch & Detailed Earnings Play Strategies - baoquankhu1.vn
Is Biohaven Ltd. (BHVN) stock outpacing its medical peers this year? - MSN
Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Biohaven (NYSE:BHVN) Stock Price Up 8.4%Should You Buy? - MarketBeat
Does Biohaven Ltd. (BHVN) Have the Potential to Rally 82.16% as Wall Street Analysts Expect? - Finviz
Goldman Sachs initiates coverage on Biohaven Pharma stock with Buy rating - Investing.com Australia
Biohaven Ltd (BHVN) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):